Sign in →

Test ID: CDTA Carbohydrate Deficient Transferrin, Adult, Serum

Reporting Name

Carb Def Transferrin, Adult, S

Useful For

An indicator of chronic alcohol abuse

Specimen Type

Serum


Advisory Information


This test is for evaluation of alcohol abuse. If the ordering physician is looking for congenital disorders of glycosylation, order CDG / Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation, Serum.



Necessary Information


1. Patient's age is required.

2. Reason for referral is required if patient is <21 years old.



Specimen Required


Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 0.1 mL


Specimen Minimum Volume

0.05 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Frozen (preferred) 45 days
  Refrigerated  28 days
  Ambient  7 days

Reference Values

≤0.10

0.11-0.12 (indeterminate)

Day(s) and Time(s) Performed

Wednesday; 8 a.m.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

82373

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CDTA Carb Def Transferrin, Adult, S In Process

 

Result ID Test Result Name Result LOINC Value
31714 Mono-oligo/Di-oligo Ratio 35469-6
31715 Interpretation 59462-2

Clinical Information

Chronic alcoholism causes a transient change in the glycosylation pattern of transferrin where the relative amounts of disialo- and asialotransferrin (carbohydrate deficient transferrin: CDT) are increased over the amount of normally glycosylated tetrasialotransferrin. This recognition led to the use of CDT in serum as a marker for chronic alcohol abuse.

 

CDT typically normalizes within several weeks of abstinence of alcohol use. However, it is important to recognize that there are other causes of abnormal CDT levels, which include congenital disorders of glycosylation and other genetic and nongenetic causes of acute or chronic liver disease.

 

CDT testing alone is not recommended for general screening for alcoholism; however, when combined with other methods (ie, gamma-glutamyltransferase, mean corpuscular volume, patient self-reporting, ethylglucuronide analysis), clinicians can expect to identify the majority of patients who consume a large amount of alcohol.

Interpretation

Patients with chronic alcoholism may develop abnormally glycosylated transferrin isoforms (ie, carbohydrate deficient transferring: CDT >0.12). CDT results from 0.11 to 0.12 are considered indeterminate.

 

Patients with liver disease due to genetic or nongenetic causes may also have abnormal results.

Clinical Reference

1. De Giovanni N, Cittadini F, Martello S: The usefulness of biomarkers of alcohol abuse in hair and serum carbohydrate-deficient transferrin: a case report. Drug Test Anal 2015 Aug;7(8):703-707

2. Fleming MF, Anton RF, Spies CD: A review of genetic, biological, pharmacological, and clinical factors that affect carbohydrate-deficient transferrin levels. Alcohol Clin Exp Res 2004;28(9):1347-1355

3. Gough G, Heathers L, Puckett D, et al: The Utility of Commonly Used Laboratory Tests to Screen for Excessive Alcohol Use in Clinical Practice. Alcohol Clin Exp Res 2015 Aug;39(8):1493-1500

4. Stibler H: Carbohydrate-deficient transferring in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 1991;37:2029-2037

5. Torrente MP, Freeman WM, Vrana KE: Protein biomarkers of alcohol abuse. Expert Rev Proteomics 2012;9(4):425-436

Analytic Time

5 days (not reported Saturday or Sunday)

Method Name

Affinity Chromatography/Mass Spectrometry (MS)

Mayo Medical Laboratories | Genetics and Pharmacogenomics Catalog Additional Information:

mml-biochemical